Seattle, Washington-based Accolade Inc. is scheduled to list its IPO on the Nasdaq Global Select Market under the symbol "ACCD" on July 2, 2020. The initial public offering price is expected to be between $19.00 and $21.00 per share.
Shares of Vaxart Inc. (VXRT) closed at a two-year high of $6.26 on Thursday, thanks to the Company's pipeline progress, especially the COVID-19 vaccine program.
The IPO activity in the U.S. pharma/biotech sector has had a strong showing in the month of June, with 14 listings so far. Now, let's take a look at the biotech IPOs scheduled for Friday, June 26, 2020.
Shares of Translate Bio Inc. (TBIO) touched an all-time high of $27.24 in intraday trading yesterday (Jun.23, 2020), thanks to the expanded collaboration with Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), to develop mRNA vaccines across all infectious disease areas.
The U.S. healthcare sector is seeing a flurry of IPO activity in June. So far this month, 10 companies have made their stock market debut. Let's take a look at the IPOs slated for tomorrow.
Royalty Pharma is an acquirer of revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products.
The company's portfolio includes royalties on over 45 commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi,...
Shares of Regeneron Pharmaceuticals Inc. (REGN), which touched an all-time high of $618.71 on June 2, 2020, have given back some of its gains and trade around $606.
The IPO activity in the U.S. healthcare sector is back with a bang this month. Five companies have gone public so far this month. (Inludes Lantern Pharma (LTRN), which is set to begin trading on June 11). Now, let's take a look at the IPOs scheduled for Friday.
The IPO activity in the U.S. healthcare sector, which has been somewhat tepid in the last two months, is picking up pace . Let's take a look at the U.S. healthcare IPOs scheduled for tomorrow.
After winning FDA nod for Xpovio in the treatment of relapsed or refractory multiple myeloma, Karyopharm Therapeutics Inc. (KPTI) is now awaiting the FDA decision on the same drug for another indication - i.e., in relapsed/refractory diffuse large B-cell lymphoma.
South San Francisco, California-based Pliant Therapeutics is slated to debut on the Nasdaq Global Market, under the symbol 'PLRX', on June 3, 2020.
Founded in 2016, Pliant Therapeutics is a clinical stage biopharmaceutical company developing novel therapies for the treatment of fibrosis.
Shares of Axcella Health Inc. (AXLA) have been dismally performing since their listing on the NASDAQ on May 9, 2019. The stock is down more than 70 percent over the last 1 year.
Irvine, California-based Inari Medical is slated to debut on the Nasdaq Global Select Market, under the symbol 'NARI', on May 22, 2020.
Epalinges, Switzerland-based ADC Therapeutics announced the pricing of initial public offering of 12.25 million shares at $19.00 per share, above the expected range of $16 to $18 per share.
The company has originally filed to sell 7.355 million shares of its common stock.
The company said that...
Epalinges, Switzerland-based ADC Therapeutics is scheduled to list its stock on the NYSE, under the symbol 'ADCT', on May 14, 2020. This is the second attempt of the company to go public. ADC Therapeutics, which is a spinoff from Spirogen Ltd., had withdrawn its IPO filing in September 2019, citing adverse market conditions.